Product Description: Inolimomab is an anti-interleukin-2 receptor (IL-2R) α chain monoclonal antibody. Inolimomab improves the survival rate in the early research of treating acute graft-versus-host disease (aGVHD)[1][2].
Applications: COVID-19-immunoregulation
Formula: N/A
References: [1] Socié G, et al. A phase 3 randomized trial comparing inolimomab vs usual care in steroid-resistant acute GVHD. Blood. 2017 Feb 2;129(5):643-649. /[2]Piñana JL, et al. Encouraging results with inolimomab (anti-IL-2 receptor) as treatment for refractory acute graft-versus-host disease. Biol Blood Marrow Transplant. 2006 Nov;12(11):1135-41.